Bengaluru-based biotechnology startup Mestastop Solutions has raised a new Rs 1.3 crores seed funding round, led by CIIE.CO and including participation from IKP Knowledge Park and Angels.

Mestastop will use the funding to scale its AI-based platform METSCAN, which characterises cancer cells using patient data samples and their assay panels to understand the cell behaviour.

It will further be utilised for running PoC animal model studies to validate proof of concept for Cancer drug discovery and repurposing. 

Currently, the company has initiated testing patient data samples as well as animal model validation. In addition to this, one international patent has been filed and another provisional patent is currently being drafted. 

Mestastop has developed three proprietary platforms - METAssay, METSCAN, and METVivo to unravel metastasis drug discovery and predictive diagnostics. The company is currently working on validating its platforms on a larger sample of patient tumours that will empower its IP creation. Previously the company also received an investment from Vistari Ventures and Mumbai Angels.